Background Arterial hypertension occurring during antiangiogenic therapy has been
correlated with the biological inhibition of the vascular endothelial growth factor-related …

Purpose Patients with metastatic colorectal cancer (mCRC) receiving all three active drugs
(irinotecan, oxaliplatin, fluorouracil) achieve the best outcome. Bevacizumab added to …

Background With the wide application of targeted drug therapies, the relevance of
prognostic and predictive markers in patient selection has become increasingly important …

Background: Hypertension (HTN) is a common toxicity of anti-VEGF (vascular endothelial
growth factor) antibody treatment. It may be a marker of VEGF signalling pathway inhibition …

Background. Hypertension is associated with antivascular endothelial growth factor
treatment, but the clinical implications of hypertension are uncertain. To assess the …

Background. Hypertension is a common toxicity of bevacizumab, but the frequency of
assessment of blood pressure and standardized grading remain to be defined. This study …

Background Hypertension is associated with the use of bevacizumab, an angiogenesis
inhibitor widely used in cancer therapy. Currently, the risk of severe hypertension associated …

Bevacizumab, a recombinant humanized monoclonal antibody targeting the vascular
endothelial growth factor (VEGF), has been approved in the US as first-and second-line …

Few predictive factors for efficacy of vascular endothelial growth factor pathway-targeted
therapies have been identified. We studied whether bevacizumab treatment-related …

Purpose Bevacizumab is a humanized monoclonal antibody targeting vascular endothelial
growth factor. The aim of this study was to gain a better understanding of the overall …